Akèy › Kansè pwostat › Massachusetts
Etid klinik pou Kansè pwostat nan Massachusetts
66 etid pou Kansè pwostat ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 12 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT07059884A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06465069Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Dana-Farber Cancer Institute at Foxborough, Foxborough
- Dana Farber-Merrimack Valley, Methuen
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, Milford
- ak 2 plis
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06632977Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Lahey Clinic, Burlington
- Lahey Clinic Peabody, Peabody
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT03866382Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
- Massachusetts General Hospital, Boston
Ap rekriteFaz 4
Laj 18 ak plis · Gason · Mizajou Sep 29, 2026 · NCT07569926Precision-Based Genomics in Prostate Cancer
- Dana Farber Cancer Institute, Boston, MA, Boston
Ap rekriteEtid obsèvasyon
Laj 18 a 120 · Gason · Mizajou Sep 28, 2026 · NCT04706663Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Sep 28, 2026 · NCT06496256A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- Greater Boston Urology, Plymouth
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou Sep 25, 2026 · NCT07832292Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Research Site, Boston
Ap rekriteFaz 1/2
Laj 18 a 130 · Gason · Mizajou Sep 25, 2026 · NCT07181161Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Dana Farber Mass General Brigham Cancer Care Inc, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Gason · Mizajou Sep 25, 2026 · NCT06800313Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
- Harvard Medical School-Massachusetts General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 25, 2026 · NCT06801236Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Sep 25, 2026 · NCT07729150A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 24, 2026 · NCT07719361Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
Ap rekriteFaz 2/3
Laj 18 a 100 · Gason · Mizajou Sep 22, 2026 · NCT06780670A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Mass General Hospital, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 22, 2026 · NCT07570979A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07114601Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Beth Israel Deaconess Med Center, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 a 100 · Gason · Mizajou Sep 22, 2026 · NCT06855277CV CARE: CardioVascular Care in PC Patients
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Sep 22, 2026 · NCT06202820A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Plymouth
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 18, 2026 · NCT06952803A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Beth Israel Deaconess Medical Center ( Site 0043), Boston
- Dana Farber Cancer Institute ( Site 0012), Boston
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 17, 2026 · NCT06925737A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Sep 15, 2026 · NCT07581184Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, Milford
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Sep 10, 2026 · NCT05946213Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Sep 10, 2026 · NCT06040125Serial MRI Scans During Radiation Therapy
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Sep 2, 2026 · NCT04188535Prostate Active Surveillance Study
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
Ap rekriteEtid obsèvasyon
Laj 21 ak plis · Gason · Mizajou Sep 2, 2026 · NCT00756665A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou Aug 21, 2026 · NCT06844383Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
- Brigham and Women's Hospital, Boston
Ap rekriteFaz 2
Laj 40 ak plis · Gason · Mizajou Aug 17, 2026 · NCT06957691FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT05919264Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- Dana-Farber Cancer Institute / Beth Israel Deaconess Medical Center, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou Aug 14, 2026 · NCT04812366Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
Ap rekriteFaz 1/2
Laj 18 a 130 · Tout sèks · Mizajou Aug 12, 2026 · NCT05417594A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Aug 10, 2026 · NCT06067841RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at Foxborough, Foxborough
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou Jul 30, 2026 · NCT05765500Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Gason · Mizajou Jul 29, 2026 · NCT05327465PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Gason · Mizajou Jul 22, 2026 · NCT06274047Jump: MR Simulation For Radiation Therapy Master Protocol
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou Jul 20, 2026 · NCT04545957Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Gason · Mizajou Jul 2, 2026 · NCT07140900Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 19 a 110 · Tout sèks · Mizajou Jun 29, 2026 · NCT02012699Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 8, 2026 · NCT04890613Androgen-responsive POSLUMA-guided Intra-prostatic Boost
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center, Milford
- ak 1 plis
Ap rekriteFaz 2
Laj 18 ak plis · Gason · Mizajou May 29, 2026 · NCT07393867Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.